NASDAQ · Health care

vTv Therapeutics Inc. (VTVT)

vTv Therapeutics Inc. brought in $36.8M of revenue over the twelve months to June 30, 2026, up 216,600.0% from a year earlier. It posted a net loss of $4.8M. At June 30, 2026 it held $86.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Price

$30.21

-1.69% on the day · September 25, 2026

52-week range $19.50 to $44.00

Market cap

$119.4M

Revenue (last 12 months)

$36.8M

+216,600.0% year on year

Net margin

-12.9%

What vTv Therapeutics Inc. does

vTv Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VTVT.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$0	-$32.8M	-$27M	n/a	n/a
2024	$1M	-$24.2M	-$18.5M	n/a	-$25.3M
2023	$0	-$25.5M	-$20.3M	n/a	-$19.1M
2022	$2M	-$22.5M	-$19.2M	n/a	-$16M
2021	$4M	-$21.7M	-$13M	n/a	-$19.3M
2020	$6.4M	-$11.9M	-$8.5M	n/a	-$18M

Next report expected around November 5, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 6, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What vTv Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 6, 2026
Quarterly report 10-Q · period to June 30, 2026
August 6, 2026
Quarterly results 8-K
July 29, 2026
Passive stake changed SCHEDULE 13G/A
June 29, 2026
Shareholder vote results 8-K
June 10, 2026
Additional proxy material DEFA14A
May 13, 2026
Securities offering prospectus 424B2
May 13, 2026
Other event 8-K
May 13, 2026
Employee stock plan registration S-8
May 13, 2026
Quarterly report 10-Q · period to March 31, 2026
May 13, 2026
Quarterly results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 29, 2026. Insider transactions on SEC

Insider trades

What the people running vTv Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about VTVT

What does vTv Therapeutics Inc. do?

vTv Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VTVT.

Is vTv Therapeutics Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $4.8M on revenue of $36.8M.

How much revenue does vTv Therapeutics Inc. make?

Over the twelve months to June 30, 2026 vTv Therapeutics Inc. reported revenue of $36.8M. That is 216,600.0% more than a year earlier.

When did vTv Therapeutics Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026.

Similar companies

Compare VTVT with

Compare VTVT with any company

Follow VTVT

Get an email when vTv Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow VTVT: get an email when it files

Where the numbers come from

Financial figures are the values vTv Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.